Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.
3.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
4.

Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial.

Braconnier A, Le Coent R, Cohen D; DEROXADO Study Group..

J Am Acad Child Adolesc Psychiatry. 2003 Jan;42(1):22-9.

PMID:
12500073
5.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
6.

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.

J Clin Psychiatry. 2006 Feb;67(2):288-96.

PMID:
16566626
7.
8.
9.

Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.

Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA; Multiple Meta-Analyses of New-Generation Antidepressants (MANGA) Study Group..

CNS Drugs. 2008;22(7):587-602. Review.

PMID:
18547127
10.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.

Eur Psychiatry. 2006 Sep;21(6):367-78. Epub 2006 May 11.

PMID:
16697153
11.

Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.

Tollefson GD, Holman SL, Sayler ME, Potvin JH.

J Clin Psychiatry. 1994 Feb;55(2):50-9.

PMID:
8077155
12.

Efficacy of controlled-release paroxetine in the treatment of late-life depression.

Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD.

J Clin Psychiatry. 2003 Sep;64(9):1065-74.

PMID:
14628982
13.

Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.

Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS.

J Clin Psychopharmacol. 2002 Apr;22(2):137-47.

PMID:
11910258
15.

Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.

Machado M, Iskedjian M, Ruiz I, Einarson TR.

Curr Med Res Opin. 2006 Sep;22(9):1825-37.

PMID:
16968586
16.
17.

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.

Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.

Psychiatry Clin Neurosci. 2007 Jun;61(3):295-307.

18.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
19.

Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.

Rapaport MH, Lydiard RB, Pitts CD, Schaefer D, Bartolic EI, Iyengar M, Carfagno M, Lipschitz A.

J Clin Psychiatry. 2009 Jan;70(1):46-57. Epub 2008 Oct 7.

PMID:
19026248
20.

Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.

Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr; Mirtazapine vs. Paroxetine Study Group..

Am J Geriatr Psychiatry. 2002 Sep-Oct;10(5):541-50.

PMID:
12213688

Supplemental Content

Support Center